Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [1043]

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia,

Post-orchiectomy miR-371 predicts recurrence in clinical stage I testicular germ cell tumours during active surveillance ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia, )

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and...

Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia,

Real-world outcomes after post-Lu177 therapy in mCRPC show limited survival and heterogeneous treatment patterns ( Dr Ben Tran - Peter MacCallum Cancer Centre, Melbourne, Australia, )

Evaluation and definition of response and progression from trials to clinical...

Dr Andrew Armstrong - Duke University, Durham, North Carolina

Evaluation and definition of response and progression from trials to clinical practice ( Dr Andrew Armstrong - Duke University, Durham, North Carolina )

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

FX-909 shows tumour regression in PPARG-high advanced urothelial carcinoma ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle...

Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA

Enfortumab vedotin and pembrolizumab improves EFS, OS, and pCR in muscle-invasive bladder cancer ( Dr Matthew Galsky - Icahn School of Medicine at Mount Sinai, New York, USA )

Latest in bladder cancer from the second half of 2025

Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone...

Latest in bladder cancer from the second half of 2025 ( Dr Alison Birtle, Dr Ignacio Durán, Prof Evanguelos Xylinas, Dr Giuseppe Simone and Dr Enrique Grande )

Do all hormone sensitive prostate cancers need triplet therapy?

Dr Deepak Dabkara - Tata Medical Center, Kolkata, India

Do all hormone sensitive prostate cancers need triplet therapy? ( Dr Deepak Dabkara - Tata Medical Center, Kolkata, India )

Panel Discussion: Case based discussions muscle invasive bladder cancer

Panelists: Dr Madhav Tiwari, Dr Tushar Dani, Dr Jaswant Jain, Dr Suneel Kaushik...

Panel Discussion: Case based discussions muscle invasive bladder cancer ( Panelists: Dr Madhav Tiwari, Dr Tushar Dani, Dr Jaswant Jain, Dr Suneel Kaushik, Dr Pradeep Chandrakar, Dr Puneet Seth, Dr Satvik Khaddar, Dr Azam Nawaz, Dr Aparna Sreevatsa, Dr Gaurav Gupta )

Choosing Wisely for genitourinary cancers

Dr Vanita Noronha - Tata Memorial Hospital, Mumbai. India

Choosing Wisely for genitourinary cancers ( Dr Vanita Noronha - Tata Memorial Hospital, Mumbai. India )

ESMO 2025: Precision medicine in bladder cancer

Dr Enrique Grande, Prof Syed Hussain, Dr Patrizia Giannatempo, Dr Félix...

ESMO 2025: Precision medicine in bladder cancer ( Dr Enrique Grande, Prof Syed Hussain, Dr Patrizia Giannatempo, Dr Félix Guerrero-Ramos )

ESMO 2025: Latest in mRCC

Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor...

ESMO 2025: Latest in mRCC ( Dr Javier Puente, Prof Jens Bedke, Prof Laurence Albiges and Prof Viktor Grünwald )

ESMO 2025: Highlights and analysis

Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada

ESMO 2025: Highlights and analysis ( Assoc Prof Bishal Gyawali - Queen's University, Kingston, Canada )

More from ecancer